Search
In May 2014, the U.S. Public Health Service released the first comprehensive clinical practice guidelines for PrEP.
Pre-Exposure Prophylaxis (PrEP) has been shown to decrease the risk of HIV infection in people who are at high risk by up to 92%, if taken consistently.
How this applies to the ED patient:
- You may start seeing more patients on only one HIV medication. The PrEP recommendation is once daily emtricitabine/tenofovir (Truvada) 200/300 mg.
- This is not a therapy that should generally be initiated in the ED as close outpatient monitioring and follow up is essential.
For more information, the CDC has a comprehensive website dedicated to PrEP.
References
Centers for Disease Control and Prevention. (2014). Pre-Exposure Prophylaxis (PrEP). Retrieved from http://www.cdc.gov/hiv/prevention/research/prep/.
Follow me on Twitter (@PharmERToxGuy) or Google Plus (+bryanhayes13)